ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Harold Varmus Addresses the NCI Board of Scientific Advisors

March 8, 2013

IOM Committee Focuses on Studies Needed To Protect Patients On Omics-Based Trials

November 4, 2011

Insulin For Diabetes Increases Risk Of Colorectal Cancer

December 31, 2004

Rauscher Disappointed In CREG Progress

October 1, 1976

NCI CTEP Approved Trials For the Month of April

April 26, 2013

PRI’s Frederick Fee $903,866 For First Six Months Of New Contract

September 2, 1988